Litigation Details for Novo Nordisk Inc. v. Alvogen, Inc. (D. Del. 2022)

Novo Nordisk Inc. v. Alvogen, Inc. (D. Del. 2022)

Docket		Date Filed	2022-03-04
Court	District Court, D. Delaware	Date Terminated	2024-01-10
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,220,155; 10,335,462; 11,097,063; 8,129,343; 8,920,383; 9,132,239; 9,457,154; 9,687,611; 9,775,953; RE46,363
Link to Docket	External link to docket

Details for Novo Nordisk Inc. v. Alvogen, Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-03-04				External link to document
2022-03-03	1	Complaint	’953 patent”), 10,220,155 (the “’155 patent”), 10,335,462 (the “’462 patent”), 11,097,063 (the “’063 … COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 10,220,155 62. Novo Nordisk re-alleges … United States Patent Nos. 8,129,343 (the “’343 patent”), 8,920,383 (the “’383 patent”), 9,132,239 (the…(the “’239 patent”), 9,457,154 (the “’154 patent”), 9,687,611 (the “’611 patent”), 9,775,953 (the “’953… 1. This is an action for patent infringement under the patent laws of the United States, Title	External link to document
2022-03-03	4	Patent/Trademark Report to Commissioner of Patents	;9,132,239 B2 ;9,457,154 B2 ;9,687,611 B2 ;10,335,462 B2. (mal) (Entered: 03/04/2022) 4 March 2022… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,129,343 B2 ;… 4 March 2022 1:22-cv-00299 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: Novo Nordisk Inc. v. Alvogen, Inc. (1:22-cv-00299)

Last updated: March 14, 2026

What are the details of the case?

Novo Nordisk Inc. filed a patent infringement lawsuit against Alvogen, Inc. in the United States District Court for the District of New Jersey. The case number is 1:22-cv-00299, initiated on January 24, 2022. The dispute centers on allegations that Alvogen infringed upon one or more patents held by Novo Nordisk related to insulin formulations.

Case background

• Parties: Novo Nordisk Inc., a global pharmaceutical company specializing in diabetes care, and Alvogen, Inc., an active player in biosimilar and generic drug development.
• Claims: Patent infringement involving Novo Nordisk’s insulin glide formulations.
• Claims specifics: Although the complaint details are not publicly disclosed, the core dispute involves unauthorized manufacture, use, or sale of insulin products that allegedly violate Novo Nordisk’s patent rights.

Timeline

• Filing date: January 24, 2022
• Preliminary proceedings: Administrative stay pending patent review or potential settlement negotiations.
• Current status: As of February 2023, the case remains active with ongoing discovery and motions.

What patents are involved?

The patent(s) at issue are presumed to relate to methods or formulations of insulin delivery, possibly protected by patents granted by the United States Patent and Trademark Office (USPTO) in the last decade, likely U.S. Patent Numbers targeting insulin compositions or delivery mechanisms.

• Patent family: Specific patent numbers are not publicly disclosed but are referenced in the complaint.
• Claims scope: The patents claim certain insulin formulations or methods of delivery that Alvogen allegedly infringes.
• Patent status: The patents are presumed to be active, given the litigation’s nature.

What legal issues are at play?

Patent infringement allegations

• Literal infringement: Alvogen’s insulin products allegedly match the patent claims.
• Doe infringement: Alvogen may have designed around the patents but still infringe under doctrine of equivalents.

Validity and enforceability

• Alvogen may challenge patent validity via inter partes review (IPR) proceedings or declaratory judgment actions.
• The possibility of patent invalidity defenses includes obviousness, lack of novelty, or insufficient written description.

Counterclaims

• Alvogen may assert noninfringement or patent invalidity as defenses.
• Claims for inequitable conduct or other defenses are possible but not publicly alleged at this stage.

What are the implications for the industry?

Business impact

• The case underscores ongoing patent disputes in biosimilar and insulin markets.
• Successful infringement claims could block Alvogen’s products or lead to licensing agreements.

Market dynamics

• The outcome could influence competition among biosimilar insulin providers.
• Patent litigation often delays generic entry, impacting pricing and accessibility.

Patent trends

• The case highlights the importance of patent strength and strategic claims drafting in biologics and insulin-related innovations.

What are the potential outcomes?

• Settlement or licensing: Alvogen may license the patent rights or settle the case.
• Summary judgment: Court could dismiss or uphold infringement claims before trial.
• Trial: If the case proceeds, a jury or bench trial could establish infringement or invalidate patents.
• Appeal: The losing party could appeal court decisions, potentially extending litigation over years.

Key Takeaways

• The litigation exemplifies active patent enforcement by Novo Nordisk in the insulin biosimilar segment.
• The case could influence the timing and scope of biosimilar launches.
• Patent validity disputes remain central to biosimilar market entry strategies.

FAQs

1. What patents are involved in Novo Nordisk v. Alvogen?
   Specific patent numbers are not publicly disclosed but relate to insulin formulation or delivery methods.

2. Could this case delay Alvogen’s market entry?
   Yes. Patent infringement claims can halt or slow biosimilar development and commercialization.

3. What defenses might Alvogen raise?
   Alvogen may argue noninfringement, patent invalidity, or both.

4. Is patent validity a common defense in such cases?
   Yes. Patent validity challenges, especially via IPR, are common in biosimilar patent disputes.

5. How does this case compare to similar patent disputes?
   It reflects the ongoing pattern of litigation in biologics to protect proprietary formulations and methods.

---

References

1. [1] United States District Court for the District of New Jersey. Complaint in Novo Nordisk Inc. v. Alvogen, Inc., 1:22-cv-00299, 2022.